CN116617247B - 一种有机超滤膜纯化分离制备的岗梅根多糖及其应用 - Google Patents
一种有机超滤膜纯化分离制备的岗梅根多糖及其应用 Download PDFInfo
- Publication number
- CN116617247B CN116617247B CN202310913208.1A CN202310913208A CN116617247B CN 116617247 B CN116617247 B CN 116617247B CN 202310913208 A CN202310913208 A CN 202310913208A CN 116617247 B CN116617247 B CN 116617247B
- Authority
- CN
- China
- Prior art keywords
- holly root
- roughhaired holly
- root polysaccharide
- polysaccharide
- roughhaired
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000004676 glycans Chemical class 0.000 title claims abstract description 142
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 142
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 142
- 241000209035 Ilex Species 0.000 title claims abstract description 122
- 235000003332 Ilex aquifolium Nutrition 0.000 title claims abstract description 122
- 235000002296 Ilex sandwicensis Nutrition 0.000 title claims abstract description 122
- 235000002294 Ilex volkensiana Nutrition 0.000 title claims abstract description 122
- 239000012528 membrane Substances 0.000 title abstract description 17
- 238000000108 ultra-filtration Methods 0.000 title abstract description 11
- 238000000746 purification Methods 0.000 title abstract description 10
- 238000000926 separation method Methods 0.000 title abstract description 10
- 210000004027 cell Anatomy 0.000 claims abstract description 44
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 9
- 229940079593 drug Drugs 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims description 21
- 150000002772 monosaccharides Chemical class 0.000 claims description 19
- 230000005764 inhibitory process Effects 0.000 claims description 10
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 230000004663 cell proliferation Effects 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract description 22
- 241000699670 Mus sp. Species 0.000 abstract description 14
- 229910052742 iron Inorganic materials 0.000 abstract description 11
- 230000034994 death Effects 0.000 abstract description 10
- 206010061218 Inflammation Diseases 0.000 abstract description 7
- 230000004054 inflammatory process Effects 0.000 abstract description 7
- 238000002474 experimental method Methods 0.000 abstract description 6
- 230000036039 immunity Effects 0.000 abstract description 6
- 230000035755 proliferation Effects 0.000 abstract description 3
- 239000011347 resin Substances 0.000 abstract description 3
- 229920005989 resin Polymers 0.000 abstract description 3
- 241000699666 Mus <mouse, genus> Species 0.000 abstract description 2
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 210000000952 spleen Anatomy 0.000 description 30
- 239000000243 solution Substances 0.000 description 28
- 230000000694 effects Effects 0.000 description 20
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 14
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 10
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 10
- 210000002540 macrophage Anatomy 0.000 description 10
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 108090001005 Interleukin-6 Proteins 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000012465 retentate Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000209094 Oryza Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- 229960004397 cyclophosphamide Drugs 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 208000019229 Spleen disease Diseases 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- OOTXFYSZXCPMPG-BMYLZFHVSA-N ursane Chemical compound C1CCC(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C)[C@H](C)[C@H]5[C@H]4CC[C@@H]3[C@]21C OOTXFYSZXCPMPG-BMYLZFHVSA-N 0.000 description 2
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- 101500000959 Bacillus anthracis Protective antigen PA-20 Proteins 0.000 description 1
- 240000000113 Baeckea frutescens Species 0.000 description 1
- 235000004335 Baeckea frutescens Nutrition 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-VANFPWTGSA-N D-mannopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-VANFPWTGSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 1
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- DKXNBNKWCZZMJT-VOXHDCLVSA-N beta-D-glucosyl-(1->4)-aldehydo-D-mannose Chemical compound O=C[C@@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O DKXNBNKWCZZMJT-VOXHDCLVSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000017306 interleukin-6 production Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229930015704 phenylpropanoid Natural products 0.000 description 1
- 150000002995 phenylpropanoid derivatives Chemical class 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- -1 polysaccharide monosaccharides Chemical class 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 150000003214 pyranose derivatives Chemical class 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Materials Engineering (AREA)
- Sustainable Development (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供了一种有机超滤膜纯化分离制备的岗梅根多糖及其应用,属于多糖技术领域。本发明通过有机超滤膜结合大孔树脂纯化分离得到不同分子量的岗梅根多糖,并且通过实验发现本发明所制备的岗梅根多糖能够有效的抑制多种肿瘤细胞的增殖并可以有效的抑制炎症导致的铁死亡。其次,本发明通过细胞小鼠实验发现,本发明所制备的岗梅根多糖能够有效的增强小鼠的免疫能力。因此,本发明扩宽了岗梅根多糖的应用范围,并为疾病的治疗提供了新的高效且安全的药物选择。
Description
技术领域
本发明属于多糖技术领域,尤其涉及一种有机超滤膜纯化分离制备的岗梅根多糖及其应用。
背景技术
岗梅根是禾本科植物岗梅(也称金粟、淘米穗)的根部。岗梅是一种常见的中药材,广泛用于中医药领域,具有较高的药用价值。岗梅根具有清热利湿、健脾和胃、利尿消肿的功效。中医药认为它味甘、性平,能够清热利湿、健脾和胃、利尿消肿。主要用于湿热病证、湿温病证、脾胃湿滞病证等的治疗。
岗梅中已报道了分离鉴定的104 个化学成分,在数目和含量上皆以三萜皂苷为主,尤其是熊果烷( 乌苏烷) 型,亦含有绿原酸、黄酮、苯丙素及木脂素,少量甾体等其他类。然而,目前关于岗梅根多糖的研究还很少,其功能尚待进一步的开发。
铁死亡是一种铁依赖的脂质过氧化引发的新型程序性细胞死亡方式,在炎症、癌症、神经退行性病变和器官损伤等病理生理学过程中发挥着非常重要的作用。巨噬细胞炎症反应关系与铁死亡关系密切。目前,关于岗梅根多糖对巨噬细胞铁死亡的调控作用尚无相关研究报道。
其次,关于岗梅根多糖在抑制肿瘤中的作用也鲜有报道,因此对其在抑制肿瘤细胞中的作用也进行了研究。
发明内容
本发明的目的在于提供一种有机超滤膜纯化分离制备的岗梅根多糖及其应用,从而扩宽岗梅根多糖的应用范围并为肿瘤疾病治疗和提高免疫提供一种安全可靠的药物。
为实现上述目的,本发明提供了如下技术方案:
首先,本发明提供了一种有机超滤膜纯化分离制备的岗梅根多糖在制备肿瘤细胞增殖抑制药物中的应用。
优选地,所述岗梅根多糖分为3种,分别为岗梅根多糖1,岗梅根多糖2,岗梅根多糖3;
所述岗梅根多糖1的单糖组成为1.04% Rha,0.70% Ara,3.05% Gal,78.98% Glc,1.29% Man,4.65% Gal-UA,5.80% Gul-UA,1.28% Glc-UA,3.22% Man-UA;所述岗梅根多糖2的单糖组成为0.73% Rha,0.45% Gal,78.53% Glc,5.75% Gal-UA,8.43% Gul-UA,1.73%Glc-UA,4.38% Man-UA;所述岗梅根多糖3的单糖组成为1.70% Rha,2.14% Ara,3.92% Gal,87.45% Glc,0.72% Man,1.29% Gal-UA,1.93% Gul-UA,0.84% Glc-UA。
优选地,所述岗梅根多糖的制备方法包括如下步骤:
(1)将岗梅根处理成渣,用乙醇回流提取除去其油脂;
(2)加入20倍量的蒸馏水80℃水浴,取上清液,再次重复操作2次,合并3次的上清液,得到岗梅根多糖提取液;
(3)将所述岗梅根多糖提取液于70℃旋蒸浓缩至原体积的20%,加入4倍体积的乙醇使乙醇浓度达到80%,4℃放置过夜,离心取沉淀,得到岗梅根粗多糖;
(4)将所述岗梅根粗多糖使用蒸馏水配置成0.1g/mL的岗梅根粗多糖溶液,按照氯仿:正丁醇=4:1的体积比例配置Sevag试剂;
(5)将所述岗梅根粗多糖溶液和Sevag试剂按照5:1的体积比例混合,重复操作8次去除蛋白;
(6)将出去蛋白的所述岗梅根粗多糖溶液和AB-8大孔树脂按照1:4的比例加入到恒温震荡器中振荡16h,脱除多糖的色素;
(7)使用10kDa的滤膜进行过滤,弃去过滤液,将截留液通过50kDa的滤膜,过滤液即为10-50kDa分子量的岗梅根多糖溶液1,将截留液再通过100kDa的滤膜,过滤液即为50-100kDa分子量的岗梅根多糖溶液2,截留液即为100kDa以上的岗梅根多糖溶液3。
(8)将岗梅根多糖溶液1,岗梅根多糖溶液2,岗梅根多糖溶液3进行冷冻干燥,即得到岗梅根多糖1,岗梅根多糖2和岗梅根多糖3。
优选地,所述肿瘤细胞包括肺癌细胞,肝癌细胞,乳腺癌细胞和结直肠癌细胞。
其次,本发明提供了一种有机超滤膜纯化分离制备的岗梅根多糖在制备抑制炎症导致的巨噬细胞铁死亡中的应用。
优选地,所述岗梅根多糖分为3种,分别为岗梅根多糖1,岗梅根多糖2,岗梅根多糖3;
所述岗梅根多糖1的单糖组成为1.04% Rha,0.70% Ara,3.05% Gal,78.98% Glc,1.29% Man,4.65% Gal-UA,5.80% Gul-UA,1.28% Glc-UA,3.22% Man-UA;
所述岗梅根多糖2的单糖组成为0.73% Rha,0.45% Gal,78.53% Glc,5.75% Gal-UA,8.43% Gul-UA,1.73% Glc-UA,4.38% Man-UA;
所述岗梅根多糖3的单糖组成为1.70% Rha,2.14% Ara,3.92% Gal,87.45% Glc,0.72% Man,1.29% Gal-UA,1.93% Gul-UA,0.84% Glc-UA。
优选地,所述岗梅根多糖由所述岗梅根多糖的制备方法制备得到。
其次,本发明提供了一种有机超滤膜纯化分离制备的岗梅根多糖在制备免疫增强药物中的应用,所述岗梅根多糖增加血液中TNF-α和IL-6的表达水平,并提高治疗个体的脾脏指数。
优选地,所述岗梅根多糖分为3种,分别为岗梅根多糖1,岗梅根多糖2,岗梅根多糖3;
所述岗梅根多糖1的单糖组成为1.04% Rha,0.70% Ara,3.05% Gal,78.98% Glc,1.29% Man,4.65% Gal-UA,5.80% Gul-UA,1.28% Glc-UA,3.22% Man-UA;
所述岗梅根多糖2的单糖组成为0.73% Rha,0.45% Gal,78.53% Glc,5.75% Gal-UA,8.43% Gul-UA,1.73% Glc-UA,4.38% Man-UA;
所述岗梅根多糖3的单糖组成为1.70% Rha,2.14% Ara,3.92% Gal,87.45% Glc,0.72% Man,1.29% Gal-UA,1.93% Gul-UA,0.84% Glc-UA。
优选地,所述岗梅根多糖由所述岗梅根多糖的制备方法制备得到。
其次,本发明提供了一种有机超滤膜纯化分离制备的岗梅根多糖在制备促进免疫低下个体血液中TNF-α和IL-6表达的促进剂中的应用,所述岗梅根多糖分为3种,分别为岗梅根多糖1,岗梅根多糖2,岗梅根多糖3;
所述岗梅根多糖1的单糖组成为1.04% Rha,0.70% Ara,3.05% Gal,78.98% Glc,1.29% Man,4.65% Gal-UA,5.80% Gul-UA,1.28% Glc-UA,3.22% Man-UA;
所述岗梅根多糖2的单糖组成为0.73% Rha,0.45% Gal,78.53% Glc,5.75% Gal-UA,8.43% Gul-UA,1.73% Glc-UA,4.38% Man-UA;
所述岗梅根多糖3的单糖组成为1.70% Rha,2.14% Ara,3.92% Gal,87.45% Glc,0.72% Man,1.29% Gal-UA,1.93% Gul-UA,0.84% Glc-UA。
本发明的有益效果在于:
本发明通过有机超滤膜纯化分离制备出了3种岗梅根多糖,同时,本发明通过细胞实验证明了本发明所制备岗梅根多糖能够有效的抑制多种的肿瘤细胞,并且可以降低炎症导致的巨噬细胞铁死亡。其次,本发明通过细胞小鼠实验发现,本发明所制备的岗梅根多糖能够有效的增强小鼠的免疫能力。因此,本发明扩宽了岗梅根多糖的应用范围,并为疾病的治疗提供了新的高效且安全的药物选择。
附图说明
图1为不同分子量岗梅根多糖的红外吸收图谱图;
图2为不同分子量岗梅根多糖的单糖组成分析的结果图;
图3为不同分子量岗梅根多糖的扫描电镜图;
图3中的(a)为放大5000倍的IAPS1电镜扫描图;图3中的(b)为放大5000倍的IAPS2电镜扫描图;图3中的(c)为放大5000倍的IAPS3电镜扫描图;图3中的(d)为放大10000倍的IAPS1电镜扫描图;图3中的(e)为放大10000倍的IAPS2电镜扫描图;图3中的(f)为放大10000倍的IAPS3电镜扫描图;
图4为不同分子量岗梅根多糖对LPS诱导的巨噬细胞ROS荧光表达影响的结果图;
图5为不同分子量岗梅根多糖对于小鼠失重率影响的结果图;
图6为不同分子量岗梅根多糖在动物试验中脾脏指数图;
图7为不同分子量岗梅根多糖处理后血液中TNF-α的含量图;
图8为不同分子量岗梅根多糖处理后血液中IL-6含量图的含量图;
图9为岗梅根多糖IAPS1处理后的脾脏HE染色切片图;
图9中的(a)为Control组的脾脏HE染色切片图;图9中的(b)为CTX组的脾脏HE染色切片图;图9中的(c)为L-IAPS1组的脾脏HE染色切片图;图9中的(d)为H-IAPS1组的脾脏HE染色切片图;图9中的(e)为Control组的淋巴HE染色切片图;图9中的(f)为CTX组的淋巴HE染色切片图;图9中的(g)为L-IAPS1组的淋巴HE染色切片图;图9中的(h)为H-IAPS1组的淋巴HE染色切片图;
图10为岗梅根多糖IAPS2处理后的脾脏HE染色切片图;
图10中的(a)为Control组的脾脏HE染色切片图;图10中的(b)为CTX组的脾脏HE染色切片图;图10中的(c)为L-IAPS2组的脾脏HE染色切片图;图10中的(d)为H-IAPS2组的脾脏HE染色切片图;图10中的(e)为Control组的淋巴HE染色切片图;图10中的(f)为CTX组的淋巴HE染色切片图;图10中的(g)为L-IAPS2组的淋巴HE染色切片图;图10中的(h)为H-IAPS2组的淋巴HE染色切片图;
图11为岗梅根多糖IAPS3处理后的脾脏HE染色切片图;
图11中的(a)为Control组的脾脏HE染色切片图;图11中的(b)为CTX组的脾脏HE染色切片图;图11中的(c)为L-IAPS3组的脾脏HE染色切片图;图11中的(d)为H-IAPS3组的脾脏HE染色切片图;图11中的(e)为Control组的淋巴HE染色切片图;图11中的(f)为CTX组的淋巴HE染色切片图;图11中的(g)为L-IAPS3组的淋巴HE染色切片图;图11中的(h)为H-IAPS3组的淋巴HE染色切片图。
具体实施方式
为使本发明的目的、技术方案和优点更加清楚明白,以下结合具体实施例,并参照附图,对本发明作进一步的详细说明。
实施例1:制备岗梅根多糖
(1)将500g岗梅根经粉碎机处理成渣,用95%乙醇3L回流提取3次除去其油脂等杂质;
(2)加入10L的蒸馏水80℃水浴,取上清液,再次重复操作2次,合并3次的上清液,得到岗梅根多糖提取液;
(3)将岗梅根多糖提取液于70℃旋蒸浓缩至原体积的20%,加入4倍体积的乙醇使乙醇浓度达到80%,4℃放置过夜,离心取沉淀,得到岗梅根粗多糖;
(4)将岗梅根粗多糖使用蒸馏水配置成500ml 0.1g/mL的岗梅根粗多糖溶液,按照氯仿:正丁醇=4:1的体积比例配置Sevag试剂;
(5)将岗梅根粗多糖溶液和Sevag试剂按照5:1的体积比例混合,重复操作8次去除蛋白;
(6)将出去蛋白的岗梅根粗多糖溶液和AB-8大孔树脂按照1:4的比例加入到恒温震荡器中振荡16h,脱除多糖的色素;
(7)使用10kDa的滤膜进行过滤,弃去过滤液,将截留液通过50kDa的滤膜,过滤液即为10-50kDa分子量的岗梅根多糖溶液1,将截留液再通过100kDa的滤膜,过滤液即为50-100kDa分子量的岗梅根多糖溶液2,截留液即为100kDa以上的岗梅根多糖溶液3。
(8)将岗梅根多糖溶液1,岗梅根多糖溶液2,岗梅根多糖溶液3进行冷冻干燥,即得到岗梅根多糖1,岗梅根多糖2和岗梅根多糖3。
实施例2:红外光谱检测多糖结构
通过红外光谱检测光谱结构,结构如图1所示,从图1可以看出,3309.16 cm-1 处宽且强的吸收带为羟基的伸缩振动峰,1613.27 cm-1 处的吸收带可能来自于吸收的水,在1405.29 cm-1附近的谱带是由C-H 的变形振动引起的。对于IAPS2 和IAPS3, 1125.41,1091.91 和1026.74 cm-1 处的吸收峰表明存在吡喃型糖。此外,864.22,757.57 和657.11cm-1 处的吸收峰是吡喃葡萄糖衍生物的特征吸收峰。
实施例3:离子色谱法检测多糖组成
使用岩藻糖、鼠李唐、***糖、半乳糖、葡萄糖、木糖、甘露糖、果糖、半乳糖醛酸葡萄糖、葡萄糖醛酸和甘露糖醛酸作为单糖标准
(1)称取样品5 mg加入1mL 2M三氟乙酸(TFA, 3 mol/L)在 121℃下加热3小时;
(2)然后,在氮气流下干燥。随后,加入50mL 水进行涡旋混合;
(3)过滤后,使用配备有 Dionex™ CarboPac™ PA20(150*3.0mm,10μm)液相色谱柱和电化学检测器的HPIC分析上清液;
(4)0.1M NaOH、0.1 M NaOH 和0.2M NaAc用作流动相,流速设定为0.5 mL/min,进样量为5uL,柱温为30℃;
(5)单糖标准溶液按上述相同方法处理,根据单糖的摩尔质量计算摩尔比;
(6)通过HPIC分析了不同分子量的岗梅根多糖样品的单糖组成,其组成是使用IC和通过匹配色谱曲线中的保留时间与单糖标准物质的保留时间来确定的,结果如表1和图2所示。
表1 不同分子量岗梅根多糖单糖组成分析
Group | Rha | Ara | Gal | Glc | Man | Gal-UA | Gul-UA | Glc-UA | Man-UA |
IAPS1 | 1.04% | 0.70% | 3.05% | 78.98% | 1.29% | 4.65% | 5.80% | 1.28% | 3.22% |
IAPS2 | 0.73% | 0.00% | 0.45% | 78.53% | 0.00% | 5.75% | 8.43% | 1.73% | 4.38% |
IAPS3 | 1.70% | 2.14% | 3.92% | 87.45% | 0.72% | 1.29% | 1.93% | 0.84% | 0.00% |
从表1和图2可以看出,IAPS1中含量最多的Glc和Gul-UA,其占比为78.98%和5.8%;IAPS2中含量最多的Glc和Gul-UA,其占比为78.53%和8.43%; IAPS3中含量最多的Glc和Gal,其占比为87.45%和3.92%。
实施例4:SEM检测多糖的结果形态
(1)使用日立S-3400N-II SEM***在20 kV的加速电压下观察了3种不同分子量岗梅根多糖的表面形态特征;
(2)借助双面碳带将样品固定在样品架上,然后使用离子溅射涂布机用铂粉末溅射,得到的结果如图3所示。
从图3可以看出,IAPS1的呈细长米粒状(图3 中的(a)、图3中的(b)),IAPS2的多糖为簇集的球状(图3 中的(c)、图3中的(d)),IAPS3为呈现较为饱满的米粒状(图3中的 (e)、图3中的(f))。
实施例5:岗梅根多糖对不同肿瘤细胞和正常细胞增殖的抑制作用
(1)将岗梅根多糖1-3(IAPS1-3)配置成100µg/ml的岗梅根多糖溶液。
(2)选择对数生长期细胞,调整4种癌细胞(肺癌细胞A549、肝癌细胞HepG2 、人乳腺癌细胞MCF-7、结肠癌细胞SW480)细胞密度为1.5×104/mL,2种正常细胞(肝细胞L-02、胚肺成纤维细胞HFL-1)密度为2.0×104/mL,细胞悬液以100 µL/孔加入96 孔培养板,每组设置3个平行,置于37 ℃、5% CO2恒温恒湿培养箱中培养;
(3)24 h 后加入10 µL的不同浓度的样品,继续培养24h 后,每孔加入10µL CCK-8溶液,培养箱孵育4 h,用酶标仪测定在450nm 处的吸光度。最后计算半数抑制浓度IC50值,实验结果如表2所示。
表2岗梅根多糖对不同肿瘤细胞和正常细胞增殖的抑制作用
Cells | IAPS1IC50 (µg/mL) | IAPS2IC50 (µg/mL) | IAPS3IC50 (µg/mL) |
A549 | 105.6 | 147.8 | 180.3 |
HepG2 | 231.3 | 262.2 | 295.9 |
SW480 | 525.4 | 552.4 | 580.8 |
MCF-7 | 893.2 | 921.4 | 956.2 |
L-02 | 922.3 | 955.7 | 989.4 |
HFL-1 | 929.9 | 960.3 | 991.5 |
从表2可以看出,人体肿瘤细胞和正常细胞的IC50 值从大到小依次为胚肺成纤维细胞HFL-1、肝细胞L02、乳腺癌细胞MCF-7、结肠癌细胞SW480、肝癌细胞HepG2、肺癌细胞A549;可以看出,岗梅根多糖对肿瘤细胞增殖的抑制作用大于正常细胞,且对肺癌细胞A375的活性最大,IC50 值为105.6 µg/mL,对胚肺成纤维细胞HFL-1的活性最小,IC50 值为929.9 µg/mL,表现出细胞选择性。且对于同一种细胞的IC50 值都呈现出IAPS1<IAPS2<IAPS3,说明低分子量的IAPS1具有更好的抑制肿瘤的活性。
实施例6:检测岗梅根多糖对于铁死亡的影响
(1)将对数生长的巨噬细胞以1.5×105/孔的密度接种于24 孔板中,待24 h 细胞贴壁,实验组使用岗梅根多糖1-3预处理1 h 后加入1 mg/mL 的LPS刺激细胞24 h;
(2)药物处理结束后,加入500 µL含2.5 µmol/L C11BODIPY581/59的无血清培养液37 ℃ 避光孵育30 min,激光共聚焦荧光显微镜下观察细胞脂质活性氧荧光表达情况,结果图4所示。
在图4中,细胞周围的白色是氧化还原后的ROS,与空白组相比,岗梅根多糖干预后的氧化还原的细胞更多,说明细胞氧化的程度明显下降,且高剂量组的氧化还原程度高于低剂量,IAPS1的氧化还原程度高于IAPS2和IAPS3。表明岗梅根多糖对LPS诱导的炎症巨噬细胞铁死亡具有抑制作用,IAPS1具有更好的抑制铁死亡的活性。
实施例7:检测岗梅根多糖对于体外免疫活性的影响
(1)将小鼠(SPF级Balb/C小鼠购自济南朋悦实验动物繁育有限公司(中国山东))分开放在笼子中,分为8组,每组5只,在标准条件下进行培养(温度为24±2℃,相对湿度50%-60%,光照周期12小时,提供常规的颗粒饲料和自来水)。所有涉及动物的实验均严格《实验动物的护理和使用》进行;
(2)分为对照组、环磷酰胺模型组(80mg/kg)、10-50 kDa岗梅根多糖低剂量组(100mg/kg)和高剂量组(200 mg/kg)、50-100 kDa岗梅根多糖低剂量组和高剂量组、100kDa以上岗梅根多糖低剂量组和高剂量组;
(3)小鼠通过5天环磷酰胺造模,造模成功后进行为期7天的岗梅根多糖治疗,每天固定时间给全部老鼠称重并记录其体重变化;
(4)通过眼球将血液收集到无菌管中,在3000r/min和4℃下离心10min以提取上清液血清并实验ELISA试剂盒测定TNF-α和IL-6。
(5)快速解剖小鼠的脾脏用PBS溶液冲洗,保存在4%多聚甲醛中固定24h,加工并包埋在石蜡中。制备5μm厚的切片并用苏木精和伊红染色。使用显微镜观察脾脏组织学和形态。
体重变化的实验结果如图5所示,在前5天环磷酰胺造模期可以发现除了对照组其余每组小鼠体重都呈下降趋势,在第6天治疗组进行治疗后,其小鼠体重呈上升趋势且有剂量依赖性,其增长率由高到低依次为:IAPS1-H>IAPS1-L>IAPS2-H>IAPS3-H>IAPS2-L>IAPS3-L>CTX,从图中可以发现治疗组的增长率高于对照组,结果表明岗梅根多糖具有免疫调节作用,而且IAPS1的效果最佳。
脾脏指数能直观的反映小鼠免疫能力高低。脾脏指数=(脾脏重量(mg))/(体重(g)),其结果如图5所示,与空白组比较,模型组的脾脏指数显著降低;而与模型组相比,通过不同分子量岗梅根多糖治疗后的IAPS组均能显著提高免疫抑制小鼠的脾脏指数,且以高剂量IAPS1效果最佳。
TNF-α为促炎细胞因子,不仅促进巨噬细胞活化和抗原呈递,而且在介导先天性和适应性免疫反应中发挥越来越大的作用。TNF-α的结果如图6所示,与对照组相比,不同分子量的岗梅根多糖以浓度依赖性方式显著增加TNF-α的产生,且IAPS1对TNF-α的影响显著高于IAPS2和IAPS3。且含量由高到低依次为IAPS1-H>IAPS1-L>IAPS2-H>IAPS2-L>IAP3S-H>IAPS3-L。这表明高剂量岗梅根多糖能够改善CTX诱导产生的炎性浸润,具有更强的免疫作用。
IL-6细胞因子的产生是评估巨噬细胞免疫调节的重要途径,其结果如图7所示。可以看出,与对照组相比,不同分子量的岗梅根多糖以浓度依赖性方式显著增加IL-6的产生,且IAPS1对IL-6的影响显著高于IAPS2和IAPS3。含量由高到低依次为IAPS1-H>IAPS1-L>IAPS2-H>IAPS2-L>IAP3S-H>IAPS3-L,说明IAPS1-H对缓解CTX模型导致的炎症效果最好。
通过脾脏组织学观察岗梅根多糖1-3对CTX诱导的免疫抑制小鼠模型的影响,结果如图9-11所示,图中黑色框为局部放大图,黑色箭头代表巨核细胞前体细胞。
从图中可以看出,对照组脾脏结构清晰,可见由排列紧密的淋巴细胞构成的脾小结和其周围含有大量红细胞的红髓,红白髓界限明显;模型组与空白组相比,细胞数量减少且结构模糊,红髓与边缘区界限不明显且多核巨细胞增多;
高剂量组IAPS1、IAPS2和IAPS3可使免疫抑制小鼠脾脏边缘区细胞数量显著增多且细胞数量增多,红白髓界限明显。
在淋巴组织中,对照组细胞排列整齐,模型组与对照组相比,多核巨细胞显著增多,通过岗梅根多糖1-3的治疗可以缓解CTX诱导的免疫抑制模型且高剂量的IAPS1、IAPS2和IAPS3对模型的病理现象明显改善。试验结果表明,不同岗梅根多糖1-3可一定程度上拮抗CTX引起的免疫器官损伤,且浓度越高改善效果越好,这将有利于维持免疫器官的正常结构和功能。
综上所述,可以看出本发明所制备的岗梅根多糖可以有效的抑制肿瘤细胞的增强,其中对于肺癌细胞的抑制效果最佳;
其次,岗梅根多糖对于炎症导致的巨噬细胞铁死亡具有抑制作用,因此可以通过巨噬细胞的活性来提供免疫能力。
其次,岗梅根多糖也可以通过调控炎症因子来缓解炎症。
Claims (1)
1.岗梅根多糖在制备肿瘤细胞增殖抑制药物中的应用,其特征在于,所述岗梅根多糖为岗梅根多糖1,所述岗梅根多糖1的单糖组成为1.04%Rha,0.70%Ara,3.05% Gal,78.98%Glc,1.29% Man,4.65% Gal-UA,5.80% Gul-UA,1.28% Glc-UA,3.22% Man-UA;
所述肿瘤细胞为肺癌细胞,肝癌细胞或结直肠癌细胞。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310913208.1A CN116617247B (zh) | 2023-07-25 | 2023-07-25 | 一种有机超滤膜纯化分离制备的岗梅根多糖及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310913208.1A CN116617247B (zh) | 2023-07-25 | 2023-07-25 | 一种有机超滤膜纯化分离制备的岗梅根多糖及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116617247A CN116617247A (zh) | 2023-08-22 |
CN116617247B true CN116617247B (zh) | 2023-09-29 |
Family
ID=87617453
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310913208.1A Active CN116617247B (zh) | 2023-07-25 | 2023-07-25 | 一种有机超滤膜纯化分离制备的岗梅根多糖及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116617247B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102784363A (zh) * | 2012-08-17 | 2012-11-21 | 郑美芳 | 一种治疗胰腺癌的中药组合物及其制备方法 |
CN107929307A (zh) * | 2017-12-29 | 2018-04-20 | 中南民族大学 | 一种竹节参多糖在制备提高肝癌患者免疫功能的药物中的应用 |
-
2023
- 2023-07-25 CN CN202310913208.1A patent/CN116617247B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102784363A (zh) * | 2012-08-17 | 2012-11-21 | 郑美芳 | 一种治疗胰腺癌的中药组合物及其制备方法 |
CN107929307A (zh) * | 2017-12-29 | 2018-04-20 | 中南民族大学 | 一种竹节参多糖在制备提高肝癌患者免疫功能的药物中的应用 |
Non-Patent Citations (6)
Title |
---|
Characterization and immunoregulatory activity of two polysaccharides from the root of Ilex asprella;Fancheng Meng et al;《Carbohydrate Polymers》;第第197卷卷;第9-16页 * |
Fancheng Meng et al.Characterization and immunoregulatory activity of two polysaccharides from the root of Ilex asprella.《Carbohydrate Polymers》.2018,第第197卷卷第9-16页. * |
Qiu Li et al.Reprogramming Tumor Associated Macrophage Phenotype by a Polysaccharide from Ilex asprella for Sarcoma Immunotherapy.《Int. J. Mol. Sci.》.2018,第第19卷卷第1-12页. * |
Reprogramming Tumor Associated Macrophage Phenotype by a Polysaccharide from Ilex asprella for Sarcoma Immunotherapy;Qiu Li et al;《Int. J. Mol. Sci.》;第第19卷卷;第1-12页 * |
岭南地区习用中药岗梅研究进展;祁银德 等;《亚太传统医药》;第第5卷卷(第第3期期);第29-32页 * |
祁银德 等.岭南地区习用中药岗梅研究进展.《亚太传统医药》.2009,第第5卷卷(第第3期期),第29-32页. * |
Also Published As
Publication number | Publication date |
---|---|
CN116617247A (zh) | 2023-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhong et al. | Polysaccharides from marine Enteromorpha: Structure and function | |
CN109400742B (zh) | 一种齿瓣石斛精制多糖及其制备方法和应用 | |
KR101725584B1 (ko) | 알로에 다당류의 조성물 및 방법 | |
CN109400741B (zh) | 一种灵芝孢子多糖的分离纯化方法 | |
CN113121718B (zh) | 一种迷果芹多糖psgp-2及其制备方法与应用 | |
CN112920287B (zh) | 具有免疫调节功效的阳春砂多糖及其制备方法和应用 | |
CN116617247B (zh) | 一种有机超滤膜纯化分离制备的岗梅根多糖及其应用 | |
Yuan et al. | Anti-cancer activity comparisons of aqueous extracts from Inonotus obliquus, Cordyceps militaris and Uncaria tomentosa in vitro and in vivo | |
CN110862463A (zh) | 具有生物活性的紫花苜蓿根部多糖及其硒化改性多糖的制备 | |
CN113105567B (zh) | 一种蝉拟青霉甘露聚糖及其制备和用途 | |
CN117500842A (zh) | Cs-4发酵菌丝体杂聚多糖及其制备方法与用途 | |
CN112794925B (zh) | 一种阳春砂多糖及其制备方法和应用 | |
CN112794923B (zh) | 川芎多糖及其制备方法、鉴定方法和应用 | |
CN114085295B (zh) | 一种铁钉菜多糖及其制备方法和应用 | |
CN116655820B (zh) | 一种藤茶酸性多糖AGP-3a及其提取分离方法和在制备抗炎化妆品中的用途 | |
CN115746157B (zh) | 一种美味扇菇多糖及其制备方法和用途 | |
CN115141288B (zh) | 知母活性多糖、知母粗多糖及制备方法和应用 | |
CN116731217B (zh) | 一种藤茶酸性多糖AGP-2a及其制备方法和在制备抗炎化妆品中的用途 | |
CN116763812B (zh) | 一种西洋参多糖及其制备的骨质疏松治疗药物和应用 | |
CN116120475B (zh) | 一种云莓均一多糖rcp-90-1及其分离纯化方法和作为抗肿瘤药物的应用 | |
CN114478821B (zh) | 可改善高脂饮食诱导后小鼠体质的桔梗多糖及其应用 | |
CN114230682B (zh) | 一种功能性香蕉多糖bpf2及其制备与应用 | |
CN114409824B (zh) | 毛霉胞外多糖及其制备方法和应用 | |
CN113024619B (zh) | 一种岩桂蒸馏后叶渣提取物及其提取方法和抗肿瘤用途 | |
CN113801249A (zh) | 一种熟地黄多糖的制备方法、产品及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |